Abstract

An analysis of benefit and cost is critical for independent advisory groups that provide evidence-based recommendations. In many countries, the role of RSV immunoprophylaxis for infants at increased risk of hospitalization is controversial because of limited benefit and high cost. The report by Ginsberg and co-workers provides evidence, that in Israel, despite the potential benefit of palivizumab prophylaxis in reducing a small number of RSV hospitalizations but no evidence of long-term benefit, the cost is difficult to justify. Ideally, a safe and effective RSV vaccine or more effective and less expensive monoclonal antibody soon will become available.

Details

Title
Patient equity and respiratory syncytial virus Immunoprophylaxis
Author
H Cody Meissner
Publication year
2019
Publication date
2019
Publisher
BioMed Central
e-ISSN
20454015
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2183224308
Copyright
Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.